Search Clinical Trials
Not Yet Recruiting
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells (External Link)
The study team will collect up to 18 teaspoons of patients' blood. This will be used this blood to grow T cells. The study team then grows the T cells …
Baylor Role:
Lead Sponsor
Not Yet Recruiting
Zinc Supplementation in Sickle Cell Disease (External Link)
The investigators propose a two-arm, double-blinded, Phase II study comparing the effects of two different daily doses of zinc (25 and 40 mg/day) in 34 patients with SCD-SS aged 15-35 …
Baylor Role:
Collaborator
Not Yet Recruiting
Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (External Link)
Approximately 15-24 subjects will participate in the treatment part of this study. Maximum of 180 mL of blood (not exceeding 3ml/kg/day) is collected from patients to grow the T cells …
Baylor Role:
Lead Sponsor
Not Yet Recruiting
Heart Coherence Training on Vascular Ehlers-Danlos Syndrome Patients (External Link)
Vascular Ehlers Danlos Syndrome (VEDS) is caused by pathogenic variants of the COL3A1 gene, resulting abnormal Type III collagen protein. This impacts the body's connective tissue and makes people with …
Baylor Role:
Lead Sponsor
Not Yet Recruiting
Tolerability of Enteral NAC in Infants (External Link)
Biliary atresia (BA), a neonatal liver disease characterized by impaired bile flow, is the most common indication for pediatric liver transplantation. The only identified treatment option other than liver transplant …
Baylor Role:
Collaborator
Not Yet Recruiting
Dexmedetomidine vs Placebo for Pediatric Cleft Palate Repair (External Link)
The eligibility of the patient to participate in this study will be determined by the Investigator on the basis of the inclusion and exclusion criteria. Consent will be obtained from …
Baylor Role:
Lead Sponsor